Literature DB >> 22044948

Factor VIII inhibitor and source of replacement therapy.

Pier Mannuccio Mannucci, Alessandro Gringeri, Elena Santagostino, Flora Peyvandi.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22044948      PMCID： PMC3259001          DOI： 10.2450/2011.0064-11

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  13 in total

Review 1.  Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

Authors:  I Scharrer; H J Ehrlich
Journal:  Haemophilia       Date:  2001-07       Impact factor: 4.287

2.  Clinical and organisational aspects of haemophilia care: the patients' view.

Authors:  Gabriele Calizzani; Romano Arcieri
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

3.  Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

4.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

5.  Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).

Authors:  P M Mannucci; A Gringeri; F Peyvandi; E Santagostino
Journal:  Haemophilia       Date:  2007-12       Impact factor: 4.287

Review 6.  Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Authors:  A Iorio; S Halimeh; S Holzhauer; N Goldenberg; E Marchesini; M Marcucci; G Young; C Bidlingmaier; L R Brandao; C E Ettingshausen; A Gringeri; G Kenet; R Knöfler; W Kreuz; K Kurnik; D Manner; E Santagostino; P M Mannucci; U Nowak-Göttl
Journal:  J Thromb Haemost       Date:  2010-03-17       Impact factor: 5.824

7.  Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.

Authors:  A R Giles; G E Rivard; J Teitel; I Walker
Journal:  Transfus Sci       Date:  1998-06

Review 8.  Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.

Authors:  G F Pierce; D Lillicrap; S W Pipe; T Vandendriessche
Journal:  J Thromb Haemost       Date:  2007-05       Impact factor: 5.824

9.  A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.

Authors:  M Rubinger; D Lillicrap; G E Rivard; J Teitel; M Carcao; C Hensman; I Walker
Journal:  Haemophilia       Date:  2008-01-08       Impact factor: 4.287

Review 10.  The management of inhibitors in haemophilia A: introduction and systematic review of current practice.

Authors:  S Paisley; J Wight; E Currie; C Knight
Journal:  Haemophilia       Date:  2003-07       Impact factor: 4.287
View more
  1 in total

1.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.